Open AccessMometasone furoate dry powder inhaler for the treatment of asthma
Author(s) -
A. V. Еmelyanov,
L A Goryachkina
Publication year - 2012
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja743
Subject(s) - mometasone furoate , evening , medicine , asthma , dry powder inhaler , morning , corticosteroid , inhaler , anesthesia , dermatology , physics , astronomy
The review is focused on inhaled mometasone furoate (Asmanex Twisthaler), a new medication for the treatment of asthma in adults and childred (12 years and older). Mometasone furoate (MF) has high antiinflammatory activity and low systemic bioavalability. MF has an excellent safety and efficacy profile in approved doses 200—800 mcg/daily od (in the evening) or bid (in the morning and in the evening). For patients with persistent asthma required treatment with an inhaled corticosteroid, MF is an excellent therapeutic choice.